Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Sep 17, 2007

bioMérieux to Design Companion Test for Ipsen Breast Cancer Compound

  • bioMérieux agreed to develop a companion test for Ipsen’s Phase I breast cancer drug candidate. The assay is intended for both the clinical development of the compound as well as a diagnostic test  potentially for future commercialization.

    BN 83495 is designed to block the steroid sulfatase enzyme (STS), which is found in hormone-dependent breast cancer in postmenopausal women. bioMérieux will devise a tool to determine the patients best suited to benefit from this STS inhibitor.

    The test will be developed on bioMérieux’ NucliSENS EasyQ® molecular diagnostics platform, using the NASBA® amplification technology. The company will will co-fund the project with Ipsen.



Be sure to take the GEN Poll

Cancer vs. Zika: What Worries You Most?

While Zika continues to garner a lot of news coverage, a Mayo Clinic survey reveals that Americans believe the country’s most significant healthcare challenge is cancer. Compared to other diseases, does the possibility of developing cancer worry you the most?

More »